S. Gillespie

发表

Pseudomonas aeruginosa intensive care unit outbreak: winnowing of transmissions with molecular and genomic typing

B. Parcell, K. Oravcová, M. Pinheiro, 2017, The Journal of hospital infection.

Routine Use of Microbial Whole Genome Sequencing in Diagnostic and Public Health Microbiology

G. Dougan, J. Parkhill, S. Bentley, 2012, PLoS pathogens.

The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.

A. Diacon, R. Dawson, S. Gillespie, 2015, The Journal of antimicrobial chemotherapy.

Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective

S. Gillespie, Stephen H. Gillespie, 2002, Antimicrobial Agents and Chemotherapy.

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Robin J. Svensson, A. Diacon, M. Hoelscher, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Anti-tuberculosis medication and the liver: dangers and recommendations in management.

N. Mcintyre, S. Gillespie, M. Hamilton, 1995, The European respiratory journal.

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses

Robin J. Svensson, A. Diacon, R. Dawson, 2017, Clinical pharmacology and therapeutics.

Chasing Koch's chimera.

F. Drobniewski, S. Niemann, P. Klatser, 2013, The Lancet. Infectious diseases.

Evolutionary Relationships among Strains of Mycobacterium tuberculosis with Few Copies of IS6110

Nalin Rastogi, P. Butcher, Andrew T Smith, 2003, Journal of bacteriology.

Molecular epidemiology of tuberculosis in London 1995–7 showing low rate of active transmission

D. Strachan, P. Butcher, F. Drobniewski, 2003 .

Molecular epidemiology of tuberculosis in London 1995–7 showing low rate of active transmission

D. Strachan, P. Butcher, F. Drobniewski, 2002, Thorax.

Estimation of the Rate of Unrecognized Cross-Contamination with Mycobacterium tuberculosis in London Microbiology Laboratories

P. Butcher, F. Drobniewski, S. Gillespie, 2002, Journal of Clinical Microbiology.

Principles and practice of clinical bacteriology

S. Gillespie, P. Hawkey, 2005 .

Emergence of optrA-mediated linezolid resistance in multiple lineages and plasmids of Enterococcus faecalis revealed by long read sequencing

N. Woodford, K. Hopkins, E. Khatamzas, 2020, bioRxiv.

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study

R. Shorten, A. Crook, A. Diacon, 2018, BMC Medicine.

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

A. Ramsay, S. Gillespie, N. Kennedy, 1993, The American review of respiratory disease.

Perspectives for systems biology in the management of tuberculosis

C. Coarfa, S. Niemann, A. Mandalakas, 2021, European Respiratory Review.

Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis.

S. Gillespie, N. Kennedy, R. Fox, 1993, The Journal of antimicrobial chemotherapy.

Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture.

S. Gillespie, Timothy D McHugh, D. O'Sullivan, 2010, Journal of medical microbiology.

Early predictors of mortality in pneumococcal bacteraemia.

S. Gillespie, I. Balakrishnan, R. Morris, 2000, The Journal of infection.

Sexually Transmitted Diseases in Prostitutes in Moshi and Arusha, Northern Tanzania

S. Gillespie, J. Elford, W. Nkya, 1991, International Journal of STD and AIDS.

Comparison of Phenotypic and Genotypic Methods for Pyrazinamide Susceptibility Testing with Mycobacterium tuberculosis

S. Gillespie, A. Davies, Timothy D McHugh, 2000, Journal of Clinical Microbiology.

Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease

Vincent O. Baron, K. Dholakia, S. Gillespie, 2017, Scientific Reports.

Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy

Juho Rousu, P. V. van Helden, S. Waddell, 2016, BMC Medicine.

Antibiotic resistance markers in genetically modified plants: a risk to human health?

S. Gillespie, P. Gay, 2005, The Lancet. Infectious diseases.

Antibiotic Resistance Protocols

S. Gillespie, Timothy D McHugh, 2018, Methods in Molecular Biology.

Gram-negative bacilli

S. Gillespie, 1994 .

Activity of moxifloxacin against mycobacteria.

S. Gillespie, O. Billington, 1999, The Journal of antimicrobial chemotherapy.

Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.

S. Gillespie, N. Sam, Timothy D McHugh, 2005, The Journal of antimicrobial chemotherapy.

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.

S. Gillespie, N. Sam, R. Morris, 2003, American journal of respiratory and critical care medicine.

Chapter 7: Fluoroquinolones in the Management of Tuberculosis

S. Gillespie, Kasha P. Singh, 2011 .

Randomized Controlled Trial of a Drug Regimen That Includes Ciproftoxacin for the Treatment of Pulmonary Tuberculosis

A. Ramsay, S. Gillespie, G. Tillotson, 1996 .

Fluoroquinolones: a new treatment for tuberculosis?

S. Gillespie, N. Kennedy, 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Management of infection with nontuberculosis mycobacteria

S. Gillespie, 2004 .

Human immunodeficiency virus type 1-related pulmonary Mycobacterium xenopi infection: a need to treat?

R. Miller, S. Gillespie, A. Ustianowski, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Biomarkers of treatment response in clinical trials of novel antituberculosis agents.

S. Gillespie, Timothy D McHugh, M. Lipman, 2007, The Lancet. Infectious diseases.

Molecular strain typing of M. tuberculosis isolates from a suspected outbreak involving a faulty bronchoscope.

S. Gillespie, Timothy D McHugh, M. Lipman, 2005, The Journal of hospital infection.

IS6110 homologs are present in multiple copies in mycobacteria other than tuberculosis-causing mycobacteria

S. Gillespie, Timothy D McHugh, L. Newport, 1997, Journal of clinical microbiology.

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.

S. Cole, M. Hoelscher, Alimuddin Zumla, 2014, The Lancet. Infectious diseases.

Moxifloxacin: a potential new drug for shortening treatment of pulmonary TB?

S. Gillespie, 2007 .

Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods

Robin J. Svensson, S. Gillespie, U. Simonsson, 2017, The Journal of antimicrobial chemotherapy.

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

K. Dooley, A. Diacon, M. Hoelscher, 2016, BMC Medicine.

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

A. Diacon, R. Dawson, S. Gillespie, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Perspective for Precision Medicine for Tuberculosis

S. Niemann, D. Schwudke, A. Mandalakas, 2020, Frontiers in Immunology.

The bacteriology of pleural infection by genetic and standard methods and its mortality significance.

R. Davies, N. Maskell, S. Gillespie, 2006, American journal of respiratory and critical care medicine.

Blood culture bottle culture of pleural fluid in pleural infection

R. Shorten, R. Davies, H. Davies, 2011, Thorax.

Qualitative assessment of the impact of socioeconomic and cultural barriers on uptake and utilisation of tuberculosis diagnostic and treatment tools in East Africa: a cross-sectional study

S. Gillespie, Augustus Aturinde, N. Ntinginya, 2021, BMJ Open.

Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania

S. Gillespie, S. Heysell, B. Mtafya, 2021, Journal of Clinical Microbiology.

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA).

K. Oravcová, S. Gillespie, D. Sloan, 2020, Journal of visualized experiments : JoVE.

Heat Inactivation Renders Sputum Safe and Preserves Mycobacterium tuberculosis RNA for Downstream Molecular Tests

S. Gillespie, A. Rachow, N. Bhatt, 2019, Journal of Clinical Microbiology.

Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.

F. Blasi, S. Gillespie, P. Hsueh, 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

High Mycobacterium tuberculosis Bacillary Loads Detected by Tuberculosis Molecular Bacterial Load Assay in Patient Stool: a Potential Alternative for Nonsputum Diagnosis and Treatment Response Monitoring of Tuberculosis

S. Gillespie, M. Joloba, W. Worodria, 2022, Microbiology spectrum.

The interpretation of nucleic acid amplification tests for tuberculosis: do rapid tests change treatment decisions?

S. Gillespie, A. Hayward, D. Enoch, 2005, The Journal of infection.

Streptococcus pseudopneumoniae Identification by Pherotype: a Method To Assist Understanding of a Potentially Emerging or Overlooked Pathogen

S. Gillespie, M. Leung, B. Charalambous, 2012, Journal of Clinical Microbiology.

Detection of Streptococcus pneumoniae in sputum samples by PCR

V. Emery, S. Gillespie, C. Ullman, 1994, Journal of clinical microbiology.

reaction? strain type and TB paradoxical tuberculosis Mycobacterium Is there a relationship between

S. Gillespie, M. Lipman, R. J. Shorten, 2005 .

Is there a relationship between Mycobacterium tuberculosis strain type and TB paradoxical reaction?

S. Gillespie, Timothy D McHugh, M. Lipman, 2005, Thorax.

Clinical Features and Serum β2-Microglobulin Levels in HIV-1 Positive and Negative Tanzanian Patients with Tuberculosis

S. Gillespie, L. Berger, N. Kennedy, 1995, International journal of STD & AIDS.

The epidemiology of Toxocara canis.

S. Gillespie, 1988, Parasitology today.

Origins and properties of Mycobacterium tuberculosis isolates in London.

F. Drobniewski, R. Pitman, S. Gillespie, 2005, Journal of medical microbiology.

Molecular methods for Mycobacterium tuberculosis strain typing: a users guide.

S. Gillespie, Timothy D McHugh, E. Kanduma, 2003, Journal of applied microbiology.

Comparison of Variable Number Tandem Repeat and IS6110-Restriction Fragment Length Polymorphism Analyses for Discrimination of High- and Low-Copy-Number IS6110 Mycobacterium tuberculosis Isolates

S. Gillespie, P. Hawkey, D. Gascoyne-Binzi, 2001, Journal of Clinical Microbiology.

Demonstration of homology between IS6110 of Mycobacterium tuberculosis and DNAs of other Mycobacterium spp.?

S. Gillespie, Timothy D McHugh, J. W. Dale, 1995, Journal of clinical microbiology.

When is an outbreak not an outbreak? Fit, divergent strains of Mycobacterium tuberculosis display independent evolution of drug resistance in a large London outbreak.

S. Gillespie, B. Charalambous, C. Jenkins, 2013, The Journal of antimicrobial chemotherapy.

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).

S. Gillespie, A. Nunn, P. Phillips, 2008, Tuberculosis.

Mycobacterium tuberculosis lineage: a naming of the parts.

S. Gillespie, Timothy D McHugh, R. J. Shorten, 2005, Tuberculosis.

Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts.

S. Gillespie, Timothy D McHugh, A. Breathnach, 2002, Microbial drug resistance.

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis

R. Shorten, A. Crook, A. Diacon, 2017, BMC Medicine.

Bacterial Load Comparison of the Three Main Lineages of Mycobacterium tuberculosis Complex in West Africa

S. Gillespie, D. Yeboah-Manu, P. Asare, 2021, Frontiers in Microbiology.

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

A. Crook, S. Gillespie, S. Meredith, 2014, The New England journal of medicine.

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

Robin J. Svensson, A. Diacon, R. Dawson, 2018, The Journal of infectious diseases.

OMNIgene.SPUTUM suppresses contaminants while maintaining Mycobacterium tuberculosis viability and obviates cold-chain transport

S. Gillespie, Carla Madeira, W. Sabiiti, 2018, ERJ Open Research.

Specificity of IS6110-based amplification assays for Mycobacterium tuberculosis complex

S. Gillespie, Timothy D McHugh, L. Newport, 1997, Journal of clinical microbiology.

Detection of Penicillin Susceptibility in Streptococcus pneumoniae by pbp2b PCR-Restriction Fragment Length Polymorphism Analysis

S. Gillespie, A. O'Neill, G. C. Whiting, 1999, Journal of Clinical Microbiology.

Modelling the within-host spread of SARS-CoV-2 infection, and the subsequent immune response, using a hybrid, multiscale, individual-based model. Part I: Macrophages

M. Chaplain, D. Hughes, S. Gillespie, 2022, bioRxiv.

Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease

S. Gillespie, S. Heysell, D. Sloan, 2022, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Simplification of the polymerase chain reaction for detection of Mycobacterium tuberculosis in the tropics.

S. Gillespie, P. Godfrey-Faussett, N. Andersson, 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Monitoring the therapy of pulmonary tuberculosis by nested polymerase chain reaction.

S. Gillespie, Timothy D McHugh, 1997, The Journal of infection.

Evaluation of the molecular bacterial load assay for detecting viable Mycobacterium tuberculosis in cerebrospinal fluid before and during tuberculous meningitis treatment

N. Phu, S. Gillespie, G. Thwaites, 2021, Tuberculosis.

Deploying a novel tuberculosis molecular bacterial load assay to assess the elimination rate of Mycobacterium tuberculosis in patients with multidrug-resistant tuberculosis in Tanzania

S. Gillespie, S. Heysell, B. Mtafya, 2020, bioRxiv.

Activity for Quantification of Early Bactericidal Culturewith Liquid and Solid Mycobacterial Direct Comparison of Xpert MTB / RIF Assay

A. Diacon, M. Hoelscher, R. Dawson, 2013 .

Evaluation of liquid culture for quantitation of Mycobacterium tuberculosis in murine models.

H. McShane, A. Hill, S. Gillespie, 2007, Vaccine.

Culture-free proof of Mycobacterium tuberculosis - a new assay for viable bacteria

S. Gillespie, J. Heyckendorf, M. Ruhwald, 2020, EBioMedicine.

The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay.

M. Hoelscher, S. Gillespie, B. Mtafya, 2018, Tuberculosis.

Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!

D. van Soolingen, S. Gillespie, L. Amaral, 2010, International journal of antimicrobial agents.

Protein binding of rifampicin is not saturated when using high-dose rifampicin

Carlijn H. C. Litjens, A. Diacon, M. Hoelscher, 2018, The Journal of antimicrobial chemotherapy.

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis

M. Hoelscher, K. Reither, S. Gillespie, 2017, Antimicrobial Agents and Chemotherapy.

Phosphorylcholine-containing antigens in bacteria from the mouth and respiratory tract.

S. Gillespie, A. Dickens, J. Lewin, 1996, Journal of medical microbiology.

Purification of native alpha-enolase from Streptococcus pneumoniae that binds plasminogen and is immunogenic.

S. Gillespie, S. Patel, J. Evans, 2002, Journal of medical microbiology.

The biological cost of antimicrobial resistance.

S. Gillespie, Timothy D McHugh, 1997, Trends in microbiology.

Impact of Azithromycin Administration for Trachoma Control on the Carriage of Antibiotic-Resistant Streptococcus pneumoniae

S. Gillespie, C. Knirsch, D. Mabey, 2003, Antimicrobial Agents and Chemotherapy.

Pathogenesis of pneumococcal infection.

S. Gillespie, I. Balakrishnan, 2000, Journal of medical microbiology.

A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs.

S. Gillespie, L. Heifets, R. Gosling, 2003, The Journal of antimicrobial chemotherapy.

A reiterative method for calculating the early bactericidal activity of antituberculosis drugs.

S. Gillespie, B. Charalambous, Roland D. Gosling, 2002, American journal of respiratory and critical care medicine.

An outbreak of penicillin resistant Streptococcus pneumoniae investigated by a polymerase chain reaction based genotyping method.

S. Gillespie, M. Kelsey, Timothy D McHugh, 1997, Journal of clinical pathology.

Novel PCR-Restriction Fragment Length Polymorphism Method for Determining Serotypes or Serogroups of Streptococcus pneumoniae Isolates

S. Gillespie, B. Charalambous, Timothy D McHugh, 2005, Journal of Clinical Microbiology.

Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care

S. Johnston, S. Gillespie, G. Sanderson, 2005, Thorax.

Aspects of pneumococcal infection including bacterial virulence, host response and vaccination.

S. Gillespie, 1989, Journal of medical microbiology.

Impact of Cotrimoxazole on Carriage and Antibiotic Resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-Infected Children in Zambia

J. Mwansa, S. Gillespie, D. Gibb, 2010, Antimicrobial Agents and Chemotherapy.

Prevalences of Pneumocystis jiroveci, Mycobacterium tuberculosis and Streptococcus pneumoniae infection in children with severe pneumonia, in a tertiary referral hospital in northern Tanzania

S. Gillespie, N. Sam, Timothy D McHugh, 2006, Annals of tropical medicine and parasitology.

The implications of model-informed drug discovery and development for tuberculosis.

O. Della Pasqua, S. Gillespie, G. Davies, 2017, Drug discovery today.

Reduction of blood C-reactive protein concentration complements the resolution of sputum bacillary load in patients on anti-tuberculosis therapy

M. Hoelscher, S. Gillespie, I. Jani, 2022, Frontiers in Immunology.

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

A. Crook, A. Diacon, R. Dawson, 2018, BMC Infectious Diseases.

Evolutionary Relationships among Strains of Mycobacterium tuberculosis with Few Copies of IS 6110

Nalin Rastogi, P. Butcher, F. Drobniewski, 2003 .

How Valid Is Single-Colony Isolation for Surveillance of Streptococcus pneumoniae Carriage?

S. Gillespie, B. Charalambous, N. Oriyo, 2008, Journal of Clinical Microbiology.

Quantitative Validation of Media for Transportation and Storage of Streptococcus pneumoniae

S. Gillespie, B. Charalambous, N. Sam, 2003, Journal of Clinical Microbiology.

Allelic variation in Streptococcus pneumoniae autolysin (N-acetyl muramoyl-L-alanine amidase)

S. Gillespie, Timothy D McHugh, A. Efstratiou, 1997, Infection and immunity.

Sequetyping: Serotyping Streptococcus pneumoniae by a Single PCR Sequencing Strategy

K. Bryson, S. Gillespie, M. Leung, 2012, Journal of Clinical Microbiology.

The adaptive potential during nasopharyngeal colonisation of Streptococcus pneumoniae.

S. Gillespie, M. Leung, B. Charalambous, 2011, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

The ethics of non-inferiority trials

S. Gillespie, S. Meredith, A. Nunn, 2008, The Lancet.

New tricks from an old dog: streptococcal necrotising soft-tissue infections

S. Gillespie, 2004, The Lancet.

Investigation of a choline phosphate synthesis pathway in Streptococcus pneumoniae: evidence for choline phosphate cytidylyltransferase activity.

S. Gillespie, G. C. Whiting, 1996, FEMS microbiology letters.

Presence of optrA-mediated linezolid resistance in multiple lineages and plasmids of Enterococcus faecalis revealed by long read sequencing

N. Woodford, K. Hopkins, E. Khatamzas, 2022, Microbiology.

Meningitis in an Irish community

S. Gillespie, M. Mcshane, 1988, The Ulster medical journal.

Molecular Diagnosis of Infectious Diseases, 2nd edition: Jochen Decker and Udo Reischl (Eds). Methods in Molecular Medicine Series. Human Press, Totowa, 2004, vxi + 464 pp., hardback, ISBN: 1-58829-221-5 (US$125.00)

S. Gillespie, 2004 .

Species of alpha-hemolytic streptococci possessing a C-polysaccharide phosphorylcholine-containing antigen

J. Raynes, S. Gillespie, K. McAdam, 1993, Infection and immunity.

Gram-positive cocci

S. Gillespie, 1994 .

Enhanced Methodologies for Detecting Phenotypic Resistance in Mycobacteria.

Vincent O. Baron, S. Gillespie, S. Lipworth, 2018, Methods in molecular biology.

Consideration of within-patient diversity highlights transmission pathways and antimicrobial resistance gene variability in vancomycin resistant Enterococcus faecium

S. Gillespie, K. Pettigrew, S. Taori, 2022, medRxiv.

Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture

Robin J. Svensson, S. Gillespie, G. Kibiki, 2019, Antimicrobial Agents and Chemotherapy.

S91 Liver function tests during tuberculosis treatment and the implications on monitoring for hepatotoxicity

A. Crook, S. Gillespie, T. McHugh, 2016, Thorax.

Evaluation of PCR in the diagnosis of tuberculosis

S. Gillespie, W. Olver, O. Billington, 1997 .

A practical approach to render tuberculosis samples safe for application of tuberculosis molecular bacterial load assay in clinical settings without a biosafety level 3 laboratory.

S. Gillespie, B. Mtafya, N. Ntinginya, 2022, Tuberculosis.

IkappaB genetic polymorphisms and invasive pneumococcal disease.

F. Vannberg, R. Davies, C. Khor, 2007, American journal of respiratory and critical care medicine.

Studies of early bactericidal activity: new insights into isoniazid pharmacokinetics.

S. Gillespie, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Detection of C-polysaccharide in serum of patients with Streptococcus pneumoniae bacteraemia.

J. Raynes, S. Gillespie, K. McAdam, 1995, Journal of clinical pathology.

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.

A. Diacon, M. Hoelscher, R. Dawson, 2015, The Journal of antimicrobial chemotherapy.

Approaches to measure the fitness of Burkholderia cepacia complex isolates.

S. Gillespie, Timothy D McHugh, J. Moore, 2010, Journal of medical microbiology.

Anoutbreak ofpenicillin resistant Streptococcus pneumoniae investigated byapolymerase chain reaction basedgenotyping method

S. Gillespie, M. Kelsey, Timothy D McHugh, 1997 .

Modelling the effects of bacterial cell state and spatial location on tuberculosis treatment: Insights from a hybrid multiscale cellular automaton model

Mark A. J. Chaplain, Gibin G. Powathil, M. Chaplain, 2016, bioRxiv.

Field Grand Challenge Frontiers in Antibiotics

S. Gillespie, 2022, Frontiers in Antibiotics.

Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

A. Copas, O. Della Pasqua, S. Gillespie, 2019, The Journal of antimicrobial chemotherapy.

Estimation of mutation rates in antibiotic research.

S. Gillespie, O. Billington, 2001, Methods in molecular medicine.

Systematic assessment of clinical and bacteriological markers for tuberculosis reveals discordance and inaccuracy of symptom-based diagnosis for treatment response monitoring

S. Gillespie, B. Mtafya, N. Ntinginya, 2022, Frontiers in Medicine.

Moxifloxacin for tuberculosis.

S. Gillespie, Michael D. Brown, M. Murphy, 2012, The Lancet. Infectious diseases.

Identification of 2-Aminothiazole-4-Carboxylate derivatives active against mycobacterium tuberculosis H37Rv and the beta-ketoacyl-ACP

G. Besra, Qosay A. E. Al-Balas, S. Gillespie, 2019 .

Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania.

A. Ramsay, S. Gillespie, N. Kennedy, 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Microbe-vector interactions in vector-borne diseases.

A. Osbourn, Geoffrey L. Smith, S. Gillespie, 2004 .

Medical Microbiology Illustrated

S. Gillespie, 1999 .

20 – Antimicrobial susceptibility

S. Gillespie, 1994 .

Identification of 2-Aminothiazole-4-Carboxylate Derivatives Active against Mycobacterium tuberculosis H37Rv and the β-Ketoacyl-ACP Synthase mtFabH

Blair F. Johnston, G. Besra, Qosay A. E. Al-Balas, 2009, PloS one.

RP59500 (Quinupristin/dalfopristin): three case reports of its use in infection due to Enterococcus faecium.

H. Prentice, S. Gillespie, I. Balakrishnan, 1998, The Journal of infection.

The role of moxifloxacin in tuberculosis therapy

S. Gillespie, 2016, European Respiratory Review.

Infection: Microbiology and Management

S. Gillespie, B. Bannister, Jane Jones, 2006 .

Medical parasitology : a practical approach

S. Gillespie, P. Hawkey, 1995 .

Comprar Topley and Wilson's Microbiology and Microbial Infections: Parasitology (include free CD) | F. E. G. Cox | 9780340885680 | Hodder Arnold

D. Despommier, D. Wakelin, S. Gillespie, 2007 .

Principles and practice of clinical parasitology

R. Pearson, S. Gillespie, 2001 .

Antibiotic Resistance Protocols

S. Gillespie, 2010, Methods in Molecular Biology.

Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model

S. Gillespie, G. Davies, Yanmin Hu, 2018, Antimicrobial Agents and Chemotherapy.

Gram-negative coccobacilli

S. Gillespie, 1994 .

Detection and identification of bacteria in clinical samples by 16S rRNA gene sequencing: comparison of two different approaches in clinical practice.

Susan Hopkins, Claire Jenkins, S. Hopkins, 2012, Journal of medical microbiology.

Medical microbiology and infection at a glance.

S. Gillespie, K. Bamford, Stephen H. Gillespie, 2003 .

Diagnosis of human toxocariasis by antigen capture enzyme linked immunosorbent assay.

R. Maizels, B. Robertson, S. Gillespie, 1993, Journal of clinical pathology.

Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates.

S. Gillespie, Timothy D McHugh, A. Dickens, 2005, The Journal of antimicrobial chemotherapy.

Fluoroquinolone-Resistant Mutants of Burkholderia cepacia

S. Gillespie, J. Pratten, Timothy D McHugh, 2007, Antimicrobial Agents and Chemotherapy.

Management of Multiple Drug-Resistant Infections

S. Gillespie, 2004, Infectious Disease.

Susceptibility of Pseudomonas pseudomallei to new beta-lactam and aminoglycoside antibiotics.

S. Gillespie, D. McEniry, D. Felmingham, 1988, The Journal of antimicrobial chemotherapy.

Methods to determine fitness in bacteria.

S. Gillespie, Timothy D McHugh, C. Pope, 2010, Methods in molecular biology.

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

R. Chaisson, A. Diacon, J. Caoili, 2021, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

O. Della Pasqua, S. Gillespie, F. Kloprogge, 2019, Scientific Reports.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

A. Diacon, M. Hoelscher, K. Reither, 2017, The Lancet. Infectious diseases.

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

A. Diacon, M. Hoelscher, D. van Soolingen, 2015, American journal of respiratory and critical care medicine.

A Concise Guide to Diagnosis

J. Goedert, V. Georgiev, S. Piscitelli, 2007 .

A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.

I. Morrissey, S. Gillespie, D. Everett, 2001, Journal of medical microbiology.

Resuscitation-promoting factors are expressed in Mycobacterium tuberculosis-infected human tissue.

M. Young, B. Henderson, S. Gillespie, 2008, Tuberculosis.

microbe–vector interactions in vector-borne diseases: Insect transmission of viruses

A. Osbourn, Geoffrey L. Smith, S. Gillespie, 2004 .

Cutaneous larva migrans

S. Gillespie, 2004, Current infectious disease reports.

The spectrum of ocular toxocariasis

S. Gillespie, A. Voller, W. Dinning, 1993, Eye.

Hatching of second-stage larvae of Toxocara canis: a rapid method for processing large numbers of worms

S. Gillespie, N. Crowcroft, 1991, Journal of Helminthology.

Detection of circulating parasite antigen and specific antibody in Toxocara canis infections.

T. Burkot, R. Maizels, B. Robertson, 1988, Clinical and experimental immunology.

Diagnosis ofhumantoxocariasis byantigen capture enzymelinked immunosorbent assay

R. Maizels, S. Gillespie, D. Bidwell, 1993 .

Toxocariasis: A practical approach to management of ocular disease

R. Maizels, S. Gillespie, R. Cooling, 1988, Eye.

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study

Julian Parkhill, Stephen D Bentley, Rodney Dawson, 2013, The Lancet. Respiratory medicine.

Whole-genome sequencing to establish relapse or reinfection with Mycobacterium tuberculosis : a retrospective observational study

S. Mwaigwisya, J. Parkhill, S. Bentley, 2013 .

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis

R. Shorten, A. Crook, A. Diacon, 2018, BMC Medicine.

Diagnosis of Parasitic Infections

S. Gillespie, 2010 .

Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.

S. Gillespie, G. Tillotson, P. Appelbaum, 2004, International journal of antimicrobial agents.

Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.

J. Ambler, S. Gillespie, A. Dickens, 2003, Microbial drug resistance.

Tools for Detection of Mycoplasma amphoriforme: a Primary Respiratory Pathogen?

T. Beattie, K. Oravcová, S. Gillespie, 2014, Journal of Clinical Microbiology.

Clinical perspectives in integrating whole-genome sequencing into the investigation of healthcare and public health outbreaks – hype or help?

B. Parcell, M. Holden, S. Gillespie, 2020, The Journal of hospital infection.

Modelling the effects of environmental heterogeneity within the lung on the tuberculosis life-cycle

R. Eftimie, S. Gillespie, R. Bowness, 2019, bioRxiv.

A spatially heterogeneous network-based metapopulation software model applied to the simulation of a pulmonary tuberculosis infection

S. Gillespie, R. Bowness, S. Dobson, 2018, Applied Network Science.

International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.

S. Gillespie, J. Verhoef, F. Meunier, 1993, The Journal of antimicrobial chemotherapy.

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children

A. Walker, Alimuddin Zumla, J. Mwansa, 2007, AIDS.

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.

A. Diacon, M. Hoelscher, Alimuddin Zumla, 2013, The Lancet. Respiratory medicine.

Antibiotic resistance in the absence of selective pressure.

S. Gillespie, Stephen H. Gillespie, 2001, International journal of antimicrobial agents.

Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae.

S. Gillespie, A. Dickens, L. Voelker, 2002, Microbial drug resistance.

A simple label-free method reveals bacterial growth dynamics and antibiotic action in real-time

S. Gillespie, R. Bowness, R. Hammond, 2021, Scientific Reports.

Physiological Cost of Rifampin Resistance Induced In Vitro in Mycobacterium tuberculosis

S. Gillespie, Timothy D McHugh, O. Billington, 1999, Antimicrobial Agents and Chemotherapy.

Incorporation of choline into Streptococcus pneumoniae cell wall antigens: evidence for choline kinase activity.

S. Gillespie, G. C. Whiting, 1996, FEMS Microbiology Letters.

Streptococcus pneumoniae Choline Binding Proteins

S. Gillespie, G. C. Whiting, 1997 .

Streptococcus pneumoniae choline binding proteins. Role in cell wall turnover.

S. Gillespie, G. C. Whiting, 1997, Advances in experimental medicine and biology.

Treatment seeking behaviours, antibiotic use and relationships to multi-drug resistance: A study of urinary tract infection patients in Kenya, Tanzania and Uganda

D. Aanensen, M. Holden, S. Gillespie, 2023, medRxiv.

The role of multidimensional poverty in antibiotic misuse: a mixed-methods study of self-medication and non-adherence in Kenya, Tanzania, and Uganda.

M. Holden, S. Gillespie, M. Kesby, 2023, The Lancet. Global health.

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

A. Crook, A. Diacon, R. Dawson, 2016, BMC Medicine.

Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin.

J. Hinds, P. Butcher, S. Gillespie, 2008, The Journal of antimicrobial chemotherapy.

Genomic Investigations Unmask Mycoplasma amphoriforme, a New Respiratory Pathogen

N. Thomson, S. Harris, J. Bryant, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Severe acute respiratory syndrome (SARS): breath-taking progress.

S. Bhagani, S. Gillespie, P. Hawkey, 2003, Journal of medical microbiology.

Improving the recovery and detection of bloodstream pathogens from blood culture

S. Gillespie, R. Hammond, K. Falconer, 2020, Journal of medical microbiology.

XDR-TB, what is it; how is it treated; and why is therapeutic failure so high?

S. Gillespie, Kasha P. Singh, 2011, Recent patents on anti-infective drug discovery.

Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution?

S. Gillespie, Timothy D McHugh, D. O’Sullivan, 2005, The Journal of antimicrobial chemotherapy.

Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery.

Christopher B. Cooper, S. Gillespie, Timothy D McHugh, 2012, The Journal of infectious diseases.

Neonatal Campylobacter Enteritis with Secondary Lactose Intolerance

S. Gillespie, M. Mcshane, C. W. B. Corkey, 1988, Acta Paediatrica Scandinavica.

Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you?

Vincent O. Baron, K. Oravcová, S. Gillespie, 2015, The Journal of antimicrobial chemotherapy.

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

A. Ramsay, S. Gillespie, G. Tillotson, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

S. Gillespie, J. Heyckendorf, N. Heinrich, 2022, Clinical microbiology reviews.

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin

A. Diacon, M. Hoelscher, R. Dawson, 2021, European Respiratory Journal.

Forecasting Clinical Dose–Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin

Robin J. Svensson, S. Wicha, S. Gillespie, 2018, Clinical pharmacology and therapeutics.

Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment

P. V. van Helden, S. Gillespie, K. Ronacher, 2011, Journal of Clinical Microbiology.

The role of the molecular laboratory in the investigation of Streptococcus pneumoniae infections.

S. Gillespie, 1999, Seminars in respiratory infections.

Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease

K. Dholakia, S. Gillespie, Mingzhou Chen, 2017, Scientific Reports.

Implications of drug-induced phenotypical resistance: Is isoniazid radicalizing M. tuberculosis?

S. Gillespie, F. Kloprogge, O. Pasqua, 2022, Frontiers in Antibiotics.

Defining dormancy in mycobacterial disease.

Vincent O. Baron, S. Gillespie, S. Lipworth, 2016, Tuberculosis.

A. Crook, A. Diacon, R. Dawson, 2019, BMC Pulmonary Medicine.

Restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolated from patients with pulmonary tuberculosis in northern Tanzania.

S. Gillespie, J. W. Dale, N. Kennedy, 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

A novel method for evaluating the antimicrobial activity of tuberculosis treatment regimens.

S. Gillespie, B. Charalambous, 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy

M. Hoelscher, S. Gillespie, G. Kibiki, 2018, Front. Immunol..

Rapid diagnosis of whooping cough using monoclonal antibody.

S. Gillespie, L. Ashworth, P. Boreland, 1988, Journal of clinical pathology.

Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay

M. Hoelscher, K. Oravcová, S. Gillespie, 2020, Thorax.

Molecular Bacterial Load Assay Concurs with Culture on NaOH-Induced Loss of Mycobacterium tuberculosis Viability

S. Gillespie, B. Mtafya, N. Ntinginya, 2019, Journal of Clinical Microbiology.

Diagnosis of Streptococcus pneumoniae pneumonia by quantitative enzyme linked immunosorbent assay of C-polysaccharide antigen.

J. Raynes, S. Gillespie, K. McAdam, 1994, Journal of clinical pathology.

Think TB! Is the diagnosis of pulmonary tuberculosis delayed by the use of antibiotics?

C. Sabin, S. Gillespie, M. Lipman, 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Direct Comparison of Xpert MTB/RIF Assay with Liquid and Solid Mycobacterial Culture for Quantification of Early Bactericidal Activity

A. Diacon, M. Hoelscher, R. Dawson, 2013, Journal of Clinical Microbiology.

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Jong Sun Park, A. Benedetti, P. Cegielski, 2018, The Lancet. Respiratory medicine.

Pitfalls of PCR: misdiagnosis of cerebral nocardia infection

A. Ramsay, S. Gillespie, Timothy D McHugh, 1995, The Lancet.

Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis.

S. Gillespie, R. McNerney, S H Gillespie, 1994, The Journal of infectious diseases.

Real-time monitoring of live mycobacteria with a microfluidic acoustic-Raman platform

Vincent O. Baron, K. Dholakia, P. Glynne-Jones, 2020, Communications Biology.

Detecting Phenotypically Resistant Mycobacterium tuberculosis Using Wavelength Modulated Raman Spectroscopy.

Vincent O. Baron, K. Dholakia, S. Gillespie, 2018, Methods in molecular biology.

microbe–vector interactions in vector-borne diseases: Specificity of Borrelia –tick vector relationships

A. Osbourn, Geoffrey L. Smith, S. Gillespie, 2004 .

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

A. Crook, S. Gillespie, A. Nunn, 2017, BMC Medicine.

Basic lymphoedema management: treatment and prevention of problems associated with lymphatic filariasis: Gerusa Dreyer, David Addiss, Patricia Dreyer, Joaquim Noroes. Hollis Publishing Company, 124 pages, paperback, ISBN 1-884186-17-3 (US$19.00)

S. Gillespie, 2004 .

Is serology helpful in the diagnosis of malaria

P. Chiodini, S. Gillespie, 1988 .

Nonrandom Association of IS6110 andMycobacterium tuberculosis: Implications for Molecular Epidemiological Studies

S. Gillespie, Timothy D McHugh, 1998, Journal of Clinical Microbiology.

Rifampicin Resistance in Tuberculosis Outbreak, London, England

S. Gillespie, C. Jenkins, Timothy D McHugh, 2005, Emerging Infectious Diseases.

Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment.

S. Gillespie, A. Davies, W. Weir, 2000, The Journal of infection.

The effect of oxidative stress on the mutation rate of Mycobacterium tuberculosis with impaired catalase/peroxidase function.

S. Gillespie, Timothy D McHugh, D. O'Sullivan, 2008, The Journal of antimicrobial chemotherapy.

Moxifloxacin Treatment of Tuberculosis

S. Gillespie, Roland D. Gosling, R. Gosling, 2004, Antimicrobial Agents and Chemotherapy.

A Practical Guide to Measuring Mutation Rates in Antibiotic Resistance

S. Gillespie, Timothy D McHugh, C. Pope, 2008, Antimicrobial Agents and Chemotherapy.

MINIREVIEW A Practical Guide to Measuring Mutation Rates in Antibiotic Resistance (cid:1)

S. Gillespie, Timothy D McHugh, C. Pope, 2008 .

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

A. Diacon, M. Hoelscher, K. Reither, 2021, Clinical Pharmacokinetics.

A spatially heterogeneous network-based metapopulation software model applied to the simulation of a pulmonary tuberculosis infection

Simon A. Dobson, Stephen Gillespie, Ruth Bowness, 2018, Applied Network Science.

IκB Genetic Polymorphisms and Invasive Pneumococcal Disease

F. Vannberg, R. Davies, C. Khor, 2007 .

PTPN22 and invasive bacterial disease

F. Vannberg, R. Davies, C. Khor, 2006, Nature Genetics.

Tuberculosis: evolution in millennia and minutes.

S. Gillespie, S H Gillespie, 2007, Biochemical Society transactions.

Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach.

A. Diacon, M. Hoelscher, R. Dawson, 2022, Acta tropica.

Mycobacterial Load Assay.

K. Oravcová, S. Gillespie, W. Sabiiti, 2017, Methods in molecular biology.

A paradigm for the molecular identification of Mycobacterium species in a routine diagnostic laboratory.

S. Gillespie, C. Jenkins, Timothy D McHugh, 2007, Journal of medical microbiology.

Genetic Polymorphisms and Invasive Pneumococcal Disease

F. Vannberg, R. Davies, C. Khor, 2007 .

Pre-clinical Microbiology — Mycobacteria

S. Gillespie, 2000 .

Treatment of tuberculosis in HIV infection.

S. Gillespie, N. Kennedy, 1993, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens.

D. Tompkins, S. Gillespie, S. Amyes, 1994, The Journal of antimicrobial chemotherapy.

Unlocking the health system barriers to maximise the uptake and utilisation of molecular diagnostics in low-income and middle-income country setting

S. Gillespie, Augustus Aturinde, N. Ntinginya, 2021, BMJ Global Health.

Real-time monitoring of live mycobacteria with a microfluidic acoustic-Raman platform

Vincent O. Baron, K. Dholakia, P. Glynne-Jones, 2020, Communications Biology.

Measurement of acute phase proteins for assessing severity of Plasmodium falciparum malaria.

P. Chiodini, J. Raynes, S. Gillespie, 1991, Journal of clinical pathology.

Update on the diagnosis of tuberculosis.

S. Gillespie, D. Goletti, D. Cirillo, 2023, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Unravelling patient pathways in the context of antibacterial resistance in East Africa

D. Aanensen, M. Holden, S. Gillespie, 2023, BMC Infectious Diseases.

Predominance of multidrug-resistant (MDR) bacteria causing urinary tract infections (UTIs) among symptomatic patients in East Africa: a call for action

S. Gillespie, S. Mshana, J. Bazira, 2023, medRxiv.

The Role of Multidimensional Poverty in Antibiotic Misuse: A Study of Self-Medication and Non-Adherence in Kenya, Tanzania, and Uganda

A. Lynch, M. Holden, S. Gillespie, 2021, Social Science Research Network.

Innovative trial designs are practical solutions for improving the treatment of tuberculosis.

M. Hoelscher, Alimuddin Zumla, S. Gillespie, 2012, The Journal of infectious diseases.

RNA-based immunity in insects.

A. Osbourn, Geoffrey L. Smith, S. Gillespie, 2004 .

Weight as a surrogate marker of treatment response in tuberculosis.

S. Gillespie, N. Kennedy, 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Effective anti-tuberculosis therapy correlates with plasma small RNA

S. Gillespie, A. Pym, I. Honeyborne, 2015, European Respiratory Journal.

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.

S. Cole, M. Hoelscher, Alimuddin Zumla, 2014, The Lancet. Infectious diseases.

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Robin J. Svensson, A. Diacon, R. Dawson, 2023, Frontiers in Pharmacology.

improving diagnosis and monitoring of treatment response in pulmonary tuberculosis using the molecular bacterial load assay (MBLA)

M. Hoelscher, K. Oravcová, S. Gillespie, 2019, bioRxiv.

Using Machine Learning for Automatic Estimation of M. Smegmatis Cell Count from Fluorescence Microscopy Images

Ognjen Arandjelovic, Stephen H. Gillespie, Daniel Vente, 2019, Precision Health and Medicine.

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Jong Sun Park, A. Benedetti, P. Cegielski, 2018, The Lancet Respiratory Medicine.

Project Sanitarium: Gaming TB - A Serious Game for a Serious Problem

Iain Donald, Karen A. Meyer, John Brengman, 2015, 2015 7th International Conference on Games and Virtual Worlds for Serious Applications (VS-Games).

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.

S. Gillespie, N. Sam, R. Morris, 2003, American Journal of Respiratory and Critical Care Medicine.

Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis.

S. Gillespie, A. Nunn, P. Phillips, 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

MOLECULAR BACTERIAL LOAD ASSAY: A FAST AND ACCURATE MEANS FOR MONITORING TUBERCULOSIS TREATMENT RESPONSE

S. Gillespie, G. Kibiki, B. Mtafya, 2017, BMJ Global Health.

Are patients on treatment for pulmonary TB who stop expectorating sputum genuinely culture negative?

S. Gillespie, Timothy D McHugh, M. Lipman, 2009, Thorax.

New polymerase chain reaction-based diagnostic techniques for bacterial respiratory infection.

S. Gillespie, 1998, Current Opinion in Infectious Diseases.

Detection and identification of bacteria in clinical samples by 16S rRNA gene sequencing: comparison of two different approaches in clinical practice.

S. Hopkins, S. Gillespie, C. Kibbler, 2012, Journal of medical microbiology.

HspX knock-out in Mycobacterium tuberculosis leads to shorter antibiotic treatment and lower relapse rate in a mouse model--a potential novel therapeutic target.

K. Oravcová, S. Gillespie, D. Mitchison, 2015, Tuberculosis.

Protein binding of rifampicin is not saturated when using high-dose rifampicin

Carlijn H. C. Litjens, A. Diacon, M. Hoelscher, 2018, The Journal of antimicrobial chemotherapy.